The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
Scientific progress often follows a prolonged path, but bioentrepreneur Samy Lamouille believes his dedication toward this pursuit will ultimately pay off for brain cancer patients.
